Commentary

Prostate cancer screening and the role of PSA: A UK perspective

Prasanna Sooriakumaran, MD, PhD, FRCSUrol, FEBU
Cleveland Clinic Journal of Medicine January 2021, 88 (1) 14-16; DOI: https://doi.org/10.3949/ccjm.88a.20164
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.

REFERENCES

  1. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    . Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1):7–30. doi:10.3322/caac.21590
    OpenUrlCrossRefPubMed
  2. ↵
    1. Prostate Cancer UK
    . About prostate cancer. https://prostatecanceruk.org/prostate-information/about-prostate-cancer. Accessed November 30, 2020.
  3. ↵
    1. Hugosson J,
    2. Roobol MJ,
    3. Mansson M,
    4. et al
    . A 16-yr follow-up of the European Randomised Study of Screening for Prostate Cancer. Eur Urol 2019; 76(1);45–51. doi:10.1016/j.eururo.2019.02.009
    OpenUrlCrossRef
  4. ↵
    1. Pinsky PF,
    2. Prorok PC,
    3. Yu K,
    4. Kramer BS,
    5. Black A
    . Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017; 123(4):592–599. doi:10.1002/cncr.30474
    OpenUrlCrossRefPubMed
  5. ↵
    1. Hamdy FC,
    2. Donovan JL,
    3. Lane JA,
    4. et al
    . 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375(15):1415–1424. doi:10.1056/NEJMoa1606220
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bryant RJ,
    2. Hobbs CP,
    3. Eyre KS,
    4. et al
    . Comparison of prostate biopsy with or without multiparametric magnetic resonance imaging for prostate cancer detection: an observational cohort study. J Urol 2019; 201(3):510–519. doi:10.1016/j.juro.2018.09.049
    OpenUrlCrossRef
  7. ↵
    1. Kasivisvanathan V,
    2. Stabile A,
    3. Neves JB,
    4. et al
    . Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the detection of prostate cancer: a systematic review and meta-analysis. Eur Urol 2019; 76(3):284–303. doi:10.1016/j.eururo.2019.04.043
    OpenUrlCrossRef
  8. ↵
    1. Lilja H,
    2. Cronin AM,
    3. Dahlin A,
    4. et al
    . Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117(6):1210–1219. doi:10.1002/cncr.25568
    OpenUrlCrossRefPubMed
  9. ↵
    1. Sooriakumaran P
    . Smarter screening for prostate cancer: for the few, not the many? A stratified approach based on baseline risk. Expert Rev Anticancer Ther 2011; 11(2):169–172. doi:10.1586/era.10.233
    OpenUrlCrossRefPubMed

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects